


IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia

Anand Padmanabhan, MD, PhD; Curtis G. Jones, BS; Shannon M. Pechauer, BS; Brian R. Curtis, PhD; Daniel W. Bougie, PhD; Mehraboon S. Irani, MD; Barbara J. Bryant, MD; Jack B. Alperin, MD; Thomas G. Deloughery, MD; Kevin P. Mulvey, MD; Binod Dhakal, MD; Renren Wen, PhD; Demin Wang, PhD; and Richard H. Aster, MD

CHEST 2017; 152(3):478-485

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.


e-Fig 1



e-Figure 1. Effect of different IVIg preparations on HIT antibody-mediated platelet activation. Three different IVIg preparations at concentrations achieved *in vivo* following treatment at the 2 gm/kg dose were added to serum samples obtained from five patients experiencing severe HIT. Samples were tested in the PEA (Low PF4) shown on the ordinate. Figures show mean +1SD of triplicate measurements. Mean values were compared with results obtained with untreated serum using the Student's t-test. Asterisks denote $p < 0.01$ (**), 0.001, (***), and 0.0001 (****).

e-Fig 2

Patient 1



e-Figure 2. IgG-specific PF4 ELISA is not affected by IVIg treatment. Platelet counts (Patient 1) are shown on the left ordinate and PF4 ELISA OD results (single measurements) on the right. Horizontal line denotes the threshold for a “very strong” PF4 ELISA test result (2.0 OD). Red dashed arrows indicate IVIg treatment at a dose of 1gm/kg body weight.